Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | LPL | P06858 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15884409 | 0.95 | EGFR (0.52) | DGAT1EGFRHSD17B10LPLLIPG | |
| SCHEMBL17474563 | 0.93 | DGAT1 (0.54) | DGAT1EGFRMAPK1SIRT2LPL | |
| SCHEMBL15726117 | 0.88 | DGAT1 (0.47) | DGAT1EGFRSMPD1HDAC1HDAC8 | |
| SCHEMBL3767677 | 0.85 | DGAT1 (0.52) | DGAT1EGFRMAPK1LPLLIPG | |
| SCHEMBL31748489 | 0.85 | DGAT1 (0.52) | DGAT1EGFRMAPK1LPLLIPG | |
| SCHEMBL28650140 | 0.85 | DGAT1 (0.47) | DGAT1EGFRMAPK1LPLLIPG | |
| SCHEMBL25179630 | 0.84 | DGAT1 (0.46) | DGAT1EGFRLPLLIPGABCB1 | |
| SCHEMBL15913151 | 0.84 | DGAT1 (0.51) | DGAT1EGFRMAPK1LPLLIPG | |
| SCHEMBL29362049 | 0.84 | DGAT1 (0.46) | DGAT1EGFRLPLLIPGABCB1 | |
| SCHEMBL544572 | 0.84 | DGAT1 (0.51) | DGAT1EGFRMAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4509500-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023222115-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | 四川汇宇制药股份有限公司 | 2023-11-23 | — | — | WO | disclosed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | disclosed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | DGAT1 481/4885EGFR 1157/4885SMPD1 772/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | DGAT1 2063/4885EGFR 4795/4885SMPD1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.